RCT shows no effect for AI coach. Livongo ups enrollment rate.

Issue 042. Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 59 percent open rate. Here's what's happening this week:

HIMSS 2020, the biggest annual conference focused on health IT, is canceled because of the COVID-19 pandemic. HIMSS bought my first company, MobiHealthNews, and I still know a lot of the people there. They made the right call, but I do worry about how this impacts the future of the organization. (The big event drives almost everything at HIMSS.) Here's hoping for the best.
Besides the above, going to try to avoid writing about COVID-19 for now. Safe to assume you all are already overwhelmed. (Apologies in advance for this week's bubonic plague doctor GIF below.)
Voluntis announced another oncology DTx deal, this time with Bristol-Myers Squibb. It also announced plans to dial back its diabetes business in

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

RCT shows no effect for AI coach. Livongo ups enrollment rate.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.